Editorial: Recent advances in rhinology 2024
- PMID: 41573057
- PMCID: PMC12819186
- DOI: 10.3389/falgy.2025.1766479
Editorial: Recent advances in rhinology 2024
Keywords: EUFOREA; allergic rhinitis; biologics; chronic rhinosinusitis; rhinology; type 2 inflammation.
Conflict of interest statement
DC Serves as Academic Manager at the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) and as Associate Editor at Frontiers in Allergy, Rhinology Section. GS Honoraria for articles, speaker and advisory boards: ALK, Bayer, GlaxoSmithKline, Haleon, Noucor, Sanofi-Regeneron, and Viatris. Chair of BSACI rhinitis guidelines, Scientific Chief Editor, Rhinology Section of Frontiers in Allergy, Vice President and AR lead for EUFOREA, and Chair/member Data Monitoring Committees on SLIT for ALK. The authors DC, GS declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
References
Publication types
LinkOut - more resources
Full Text Sources
